Kimura S, Matsuda J, Ikematsu S, Miyazono K, Ito A, Nakahata T, Minamitani M, Shimada K, Shiokawa Y, Takaku F
Department of Infectious Diseases and Applied Immunology, University of Tokyo, Japan.
AIDS. 1990 Dec;4(12):1251-5. doi: 10.1097/00002030-199012000-00011.
The efficacy of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on neutropenia was evaluated in 14 patients with AIDS and AIDS-related complex (ARC). In all patients, including 11 neutropenic patients, 100 or 200 micrograms/m2 of rhG-CSF significantly increased the neutrophil counts. The response was greater in patients with higher neutrophil counts before the treatment, and was also dose-dependent. Although the effect seemed to be less potent, the agent also increased the neutrophil counts even when zidovudine (azidothymidine, AZT) and other myelosuppressive antiviral agents were administered simultaneously. These observations indicate that rhG-CSF may be beneficial in preventing and treating some secondary infections, and will make it easier to continue therapy with antiviral agents in patients with AIDS or ARC.
在14例艾滋病患者及艾滋病相关综合征（ARC）患者中评估了重组人粒细胞集落刺激因子（rhG-CSF）对中性粒细胞减少症的疗效。在所有患者中，包括11例中性粒细胞减少患者，100或200微克/平方米的rhG-CSF显著增加了中性粒细胞计数。治疗前中性粒细胞计数较高的患者反应更大，且呈剂量依赖性。尽管效果似乎较弱，但即使同时给予齐多夫定（叠氮胸苷，AZT）和其他骨髓抑制性抗病毒药物，该药物也能增加中性粒细胞计数。这些观察结果表明，rhG-CSF可能有助于预防和治疗一些继发感染，并将使艾滋病或ARC患者更容易继续使用抗病毒药物进行治疗。
